Carelife

Carelife Biotech is a Taiwan-based biotechnology company specializing in regenerative medicine and stem cell-based therapeutics. Founded in 2002, the company operates a dual business model that combines stem cell banking services with the development of innovative cell therapies. Its R&D pipeline focuses on utilizing mesenchymal stem cells (MSCs) to treat high-unmet-need conditions, including ischemic stroke, spinal cord injury, and osteoarthritis. Carelife maintains a state-of-the-art GMP-certified cell manufacturing facility to support its clinical trials and commercial banking operations. The company is publicly traded on the Taipei Exchange and is a key player in the Asian regenerative medicine sector.